GAO, Senators Call Out Shortcomings In FDA Foreign Inspections

During a Senate hearing on Tuesday (June 2), the head of Congress’ oversight arm’s health division called FDA out for what she asserts are significant problems with the way the agency manages its foreign drug inspection program, and she questioned the agency’s decision to halt foreign inspections during the COVID-19 pandemic. Lawmakers from both sides of the aisle agreed with the concerns and urged FDA to revamp its foreign inspection processes, including its practice of giving foreign facilities advance notice...